OR WAIT null SECS
© 2024 MJH Life Sciences and Consultant Live. All rights reserved.
November 09, 2022
A panel of experts in hematology discuss the future directions for sickle cell disease and share practice pearls for disease management.
Matthew M. Heeney, MD, and Nirmish Shah, MD, hypothesize about the ability of emerging sickle cell disease biomarkers to assess risk-benefit and disease severity in patients.
Nirmish Shah, MD, and Matthew M. Heeney, MD, discuss the need for ongoing clinical trials and diversity in them to bolster data and improve provider confidence in emerging therapeutic options for sickle cell disease.
November 02, 2022
Dr Elna Saah highlights the role of data longevity, clinical trial end points, and metrics when evaluating novel treatments for the management of sickle cell disease.